BR0016231A - Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções - Google Patents

Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções

Info

Publication number
BR0016231A
BR0016231A BR0016231-0A BR0016231A BR0016231A BR 0016231 A BR0016231 A BR 0016231A BR 0016231 A BR0016231 A BR 0016231A BR 0016231 A BR0016231 A BR 0016231A
Authority
BR
Brazil
Prior art keywords
carbohydrate
releases
cell surface
treatment
surface protein
Prior art date
Application number
BR0016231-0A
Other languages
English (en)
Other versions
BRPI0016231B8 (pt
BRPI0016231B1 (pt
Inventor
Lin Liu
Humg-Yu Hsiao
Douglas W Fodge
David M Anderson
Original Assignee
Chemgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemgen Corp filed Critical Chemgen Corp
Publication of BR0016231A publication Critical patent/BR0016231A/pt
Publication of BRPI0016231B1 publication Critical patent/BRPI0016231B1/pt
Publication of BRPI0016231B8 publication Critical patent/BRPI0016231B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

"COMPOSIçãO COMPREENDENDO ENZIMA COM CAPACIDADE DE CLIVAR UMA LIGAçãO QUE EFETUA A LIBERAçãO DE UMA PROTEìNA OU CARBOIDRATO DE SUPERFìCIE CELULAR PARA SER USADA NO TRATAMENTO DE INFECçõES". Enzimas de uma classe particular, caracterizadas pela capacidade de clivar uma ligação que efetua a liberação de uma proteína ou carboidrato de superfície celular, que não contêm um agente antiinfecção, apresentam significativa atividade antiinfecciosa. Sob administração oral, essas enzimas são eficazes, por exemplo, no tratamento de infecções do trato digestivo em humanos e em animais. Posteriormente, há benefícios de uma taxa de crescimento, eficácia de alimento, e saúde gerais significativamente aumentadas.
BRPI0016231A 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo BRPI0016231B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16993599P 1999-12-10 1999-12-10
PCT/US2000/033466 WO2001041785A2 (en) 1999-12-10 2000-12-08 Enzyme treatment for infection

Publications (3)

Publication Number Publication Date
BR0016231A true BR0016231A (pt) 2003-06-24
BRPI0016231B1 BRPI0016231B1 (pt) 2016-10-04
BRPI0016231B8 BRPI0016231B8 (pt) 2021-05-25

Family

ID=22617824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0016231A BRPI0016231B8 (pt) 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo

Country Status (31)

Country Link
US (2) US6780628B2 (pt)
EP (1) EP1239872B1 (pt)
JP (1) JP4871473B2 (pt)
KR (1) KR100639746B1 (pt)
CN (3) CN1433319A (pt)
AR (2) AR026764A1 (pt)
AT (1) ATE481981T1 (pt)
AU (1) AU782831B2 (pt)
BR (1) BRPI0016231B8 (pt)
CA (1) CA2394856C (pt)
CL (1) CL2008000057A1 (pt)
CO (1) CO5280226A1 (pt)
CR (1) CR6674A (pt)
CZ (1) CZ304925B6 (pt)
DE (1) DE60045010D1 (pt)
DK (1) DK1239872T3 (pt)
ES (1) ES2353371T3 (pt)
HU (1) HU230301B1 (pt)
IL (2) IL150048A0 (pt)
IN (1) IN247731B (pt)
MX (1) MX264033B (pt)
MY (1) MY124714A (pt)
NZ (1) NZ519404A (pt)
PH (1) PH12000003381B1 (pt)
PL (1) PL203054B1 (pt)
PT (1) PT1239872E (pt)
RU (1) RU2272419C2 (pt)
SK (1) SK287956B6 (pt)
TW (1) TWI255189B (pt)
UA (1) UA78486C2 (pt)
WO (1) WO2001041785A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
AU2005332655A1 (en) * 2004-10-20 2006-12-14 Iogenetics, Llc Biocides
US8916151B2 (en) 2005-04-25 2014-12-23 Cls Therapeutics Limited Method for treating a reduction of fertility
SI1973561T1 (sl) 2005-12-15 2011-07-29 Chemgen Corp Encimi, ki zmanjĺ ujejo imunski stres
PL2095825T3 (pl) 2006-11-28 2011-12-30 Cls Therapeutics Ltd Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu
HUE025717T2 (en) * 2007-06-08 2016-04-28 Australian Poultry Crc Pty Ltd Clostridium NetB toxin
BRPI0820818A2 (pt) * 2007-12-20 2015-06-16 Danisco Us Inc Controle e prevenção enzimática de biofilme
DK2254591T3 (da) * 2008-02-08 2017-11-06 Prothera Inc Inhibering eller behandling af gastrointestinal biofilm
PT2814331T (pt) 2012-02-16 2019-02-12 Elanco Us Inc Métodos e composições para redução do impacto ambiental de resíduos animais
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
TWI656872B (zh) 2014-11-13 2019-04-21 美商益農美國公司 甲基鹽黴素於豬飼料中之抗病毒效果
EP3297657B1 (en) 2015-05-22 2020-03-25 GENKIN, Dmitry Dmitrievich Extracellular dna as a therapeutic target in neurodegeneration
CN106119221A (zh) * 2016-06-28 2016-11-16 浙江省农业科学院 磷脂酰肌醇特异性磷脂酶c基因、载体、工程菌及应用
CN106318925B (zh) * 2016-08-19 2021-04-02 浙江省农业科学院 利用枯草芽孢杆菌高效表达pi-plc基因的方法
CN106615691B (zh) * 2016-10-11 2019-07-02 上海国龙生物技术集团有限公司 一种抗感染酶复合剂及其在饲料中的应用
US10501730B2 (en) * 2017-05-30 2019-12-10 Ab Enzymes Oy Mannanase variants
EP3740581A4 (en) 2018-01-16 2021-10-27 CLS Therapeutics Limited TREATMENT OF DISEASES BY LIVER EXPRESSION OF AN ENZYME WITH DESOXYRIBONUCLEASE (DNASE) ACTIVITY
MX2020009045A (es) * 2018-03-02 2020-10-12 Evonik Operations Gmbh Procedimiento in vitro para detectar disfuncion de la barrera intestinal en animales mediante la determinacion de ovotransferrina.
RU2720471C1 (ru) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Кормовая добавка для цыплят-бройлеров

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
JPS5534039A (en) 1978-08-30 1980-03-10 Hiroo Ikezawa Preparation of phsophatidylinositol phospholipase c from bacillus thuringiensis
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
US5049379A (en) 1987-07-27 1991-09-17 Wisconsin Alumni Research Foundation Fungicidal toxin and method and inoculum for controlling root rot and damping off
US4877738A (en) 1986-07-25 1989-10-31 Wisconsin Alumni Research Foundation Biological control of damping off and root rot and inoculum preparation therefor
JPH0338530A (ja) * 1989-07-03 1991-02-19 Ajinomoto Co Inc 抗真菌剤
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
DK0531437T3 (da) * 1990-05-29 1998-08-31 Chemgen Corp Hemicellulasetilskud med henblik på at forbedre energiudnyttelsen af hemicelluloseholdige levnedsmidler og dyrefoder
EP0477739A3 (en) 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
JPH07184642A (ja) * 1993-12-27 1995-07-25 Toagosei Co Ltd ホスホリパーゼｃの生産方法
MY134684A (en) * 1995-05-15 2007-12-31 Gist Brocades Bv Application of phospholipases in animal feed
EP0743017B1 (en) * 1995-05-15 2004-09-29 DSM IP Assets B.V. Application of phospholipases in animal feed
JPH08332032A (ja) * 1995-06-12 1996-12-17 Showa Denko Kk 動物経口物用酵素剤及びその用途
JP3914585B2 (ja) * 1995-10-19 2007-05-16 イーエヌ大塚製薬株式会社 マクロファージ一酸化窒素産生亢進剤
CN1092495C (zh) * 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
US6162473A (en) * 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
JPH1045581A (ja) * 1996-07-29 1998-02-17 Hideyo Yamaguchi 好中球機能低下抑制剤又は感染防御剤
WO1998018912A1 (en) * 1996-10-31 1998-05-07 Novo Nordisk A/S Novel phospholipase, production and use thereof
AU753232B2 (en) 1998-10-15 2002-10-10 Dsm N.V. Antimicrobial enzymes in animal feed
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US20020116028A1 (en) * 2001-02-20 2002-08-22 Wilson Greatbatch MRI-compatible pacemaker with pulse carrying photonic catheter providing VOO functionality

Also Published As

Publication number Publication date
AU2577601A (en) 2001-06-18
SK8262002A3 (en) 2002-12-03
ATE481981T1 (de) 2010-10-15
NZ519404A (en) 2004-05-28
MX264033B (es) 2009-01-22
IN247731B (pt) 2011-05-13
CN102172262A (zh) 2011-09-07
IN2002DE00585A (pt) 2009-03-20
US7723091B2 (en) 2010-05-25
DE60045010D1 (de) 2010-11-04
CN1433319A (zh) 2003-07-30
TWI255189B (en) 2006-05-21
CN101327320A (zh) 2008-12-24
PL356175A1 (en) 2004-06-14
MY124714A (en) 2006-06-30
HUP0203402A3 (en) 2004-12-28
RU2272419C2 (ru) 2006-03-27
EP1239872B1 (en) 2010-09-22
AR026764A1 (es) 2003-02-26
CA2394856C (en) 2011-05-10
WO2001041785A2 (en) 2001-06-14
CL2008000057A1 (es) 2008-03-14
CR6674A (es) 2007-02-22
SK287956B6 (sk) 2012-07-03
IL150048A0 (en) 2002-12-01
KR100639746B1 (ko) 2006-10-30
EP1239872A2 (en) 2002-09-18
KR20020069204A (ko) 2002-08-29
HU230301B1 (hu) 2015-12-28
US20040223961A1 (en) 2004-11-11
UA78486C2 (uk) 2007-04-10
PL203054B1 (pl) 2009-08-31
CO5280226A1 (es) 2003-05-30
US20020048576A1 (en) 2002-04-25
US6780628B2 (en) 2004-08-24
AR089799A2 (es) 2014-09-17
IL150048A (en) 2016-09-29
PT1239872E (pt) 2010-12-03
CN102172262B (zh) 2014-03-05
BRPI0016231B8 (pt) 2021-05-25
HUP0203402A2 (hu) 2003-02-28
CZ20022007A3 (cs) 2002-11-13
AU782831B2 (en) 2005-09-01
PH12000003381B1 (en) 2010-04-16
WO2001041785A3 (en) 2002-01-24
MXPA02005735A (es) 2003-10-14
CZ304925B6 (cs) 2015-01-28
CA2394856A1 (en) 2001-06-14
JP2003520207A (ja) 2003-07-02
ES2353371T3 (es) 2011-03-01
DK1239872T3 (da) 2010-10-25
BRPI0016231B1 (pt) 2016-10-04
JP4871473B2 (ja) 2012-02-08

Similar Documents

Publication Publication Date Title
BR0016231A (pt) Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções
BR0007166A (pt) Método para aumentar a atividade dos animais de estimação
DE69531104D1 (de) Transdermales system zur verabreichung durch entepithelisierte haut
CA2383714A1 (en) Method for improving the skin and coat of pets
DK0671942T3 (da) Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf
EP0382355A3 (en) Growth promoting agent for bacteria containing pullulan and/or dextran
IT1307850B1 (it) Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
DE60122672D1 (de) Zusammensetzung zur intestinalen verabreichung
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
BR9811548A (pt) Secreções maternas imunes e seu uso no tratamento e/ou profilaxia de condições do corpo humano
WO1999012552A8 (en) 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
CA2301872A1 (en) 8a-azalides as veterinary antimicrobial agents
BR9908143A (pt) Composições para a redução da atividade enzimática, utilização de ácido dissuccìnico de etileno diamina, utilização de um agente de complexação, artigo absorvente, desodorante, e utilização de composição
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
TH54151A (th) องค์ประกอบซึ่งประกอบรวมด้วยเอนไซม์สำหรับรักษาการติดเชื้อของทางเดินอาหาร
Pellegrin et al. Response to infection in patients with acute leukemia during remission induction treatment: Ceftazidime versus cefotaxime+ tobramycin.
WO2002038103A3 (en) Probiotic compositions and methods against bacterial infection in livestock animals
EP1779853A3 (en) 9a-azalides as veterinary antimicrobial agents
TH54151B (th) การรักษาการติดเชื้อด้วยเอนไซม์
RU95102208A (ru) Средство лечения эндометрита у коров
TH49215B (th) องค์ประกอบซึ่งประกอบรวมด้วยเอนไซม์สำหรับรักษาการติดเชื้อของทางเดินอาหาร

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELI LILLY AND COMPANY (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/12/2020